On April 30, 2026 Oxcia AB reported that the abstract "Interim results of the phase I/II study investigating karonudib in patients with refractory hematological malignancies paired with ex-vivo precision screen drug sensitivity screening" has been selected by the European Hematological Association (EHA) (Free EHA Whitepaper) Scientific Program Committee for a poster presentation during the EHA (Free EHA Whitepaper)2026 Congress. The congress takes place in Stockholm this year, June 11-14th. Stefan Deneberg, Principal Investigator of the clinical study and Austin Smith, Oxcia’s Chief Medical Officer, will present the interim results.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The overall aim of the clinical study is to build on early encouraging signals of clinical activity and generate the data required to support a pivotal Phase II program in Acute Myeloid Leukemia. The on-going expansion group in the OXC-101 and idarubicin combination has expanded to Denmark and Serbia to facilitate timely recruitment.
OXC-101 (karonudib) has, as previously communicated, been granted ODD status by both the EMA and the FDA for Acute Myeloid Leukemia.
(Press release, Oxcia, APR 30, 2026, View Source;utm_medium=rss&utm_campaign=oxc-101-for-aml-accepted-to-be-presented-at-eha [SID1234664973])